🇺🇸 FDA
Pipeline program

90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).

C33237/1099

Phase 1 small_molecule completed

Quick answer

90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B). for Pain is a Phase 1 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Pain
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials